Background {#Sec1}
==========

The gut is a critical target organ for many kinds of stress such as trauma, burn, shock, bleeding, and infection \[[@CR1]\]. A severe insult to the gut is believed to promote infectious complications and multiple organ dysfunction syndrome, the causes of which include deterioration of the intestinal epithelium, the immune system, and commensal bacteria \[[@CR2]\]. Normal gut microbiota have an important role in metabolism, nutrition, and protection against pathogens \[[@CR3]\]. Disruption of the gut microbiota, or "dysbiosis", could lead to many diseases such as infection, inflammatory bowel disease, metabolic syndrome, and cancer. In critically ill patients, the gut microbiota is altered significantly especially with regard to the number of obligate anaerobes, which are the dominant bacteria and are associated with infectious complications and mortality \[[@CR4]\].

Probiotics are defined by the Food and Agriculture Organization (FAO)/World Health organization (WHO) as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host and are widely used as a live microbial food supplement that can improve the intestinal microbial balance \[[@CR5]\]. *Lactobacillus* and *Bifidobacterium* are popular probiotics. Probiotics have been shown to exert health benefits, such as an anticolon cancer effect and resistance to enteric pathogens, immune system modulation, allergy, inflammatory bowel diseases, and necrotizing enterocolitis \[[@CR6]\]. Prebiotics are defined as a nondigestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacterial species in the colon \[[@CR7]\]. Synbiotics consist of probiotics and prebiotics. There are several reports on the effects of probiotics and synbiotics in sepsis patients. Shimizu et al. \[[@CR8]\] reported that 29 patients with systemic inflammatory response syndrome who received *Bifidobacterium breve* strain Yakult and *Lactobacillus casei* strain Shirota had fewer complications of diarrhea during their intensive care unit (ICU) stay. For critically ill patients, probiotics and synbiotics reduced infectious complications, especially for elective surgery and trauma \[[@CR9]\]. There are few reports on the effects of probiotics and synbiotics in sepsis patients. Therefore, the objective of this study was to evaluate whether synbiotics maintain the microbiota and reduce infectious complications in mechanically ventilated patients with sepsis.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients who were more than 16 years old and were placed on a ventilator within 3 days after admission to the ICU, and who were diagnosed as having sepsis in the Department of Traumatology and Acute Critical Medicine, Osaka University Medical School, and Osaka General Medical Center during the period November 2011 to September 2016, were eligible for enrollment in this randomized controlled study \[[@CR10]\]. Patients were randomly assigned in a 1:1 ratio to treatment groups using permutation blocks (*n* = 4 per block). The allocation sequence was generated by the corresponding author. The sequence was kept secure from all study personnel responsible for screening and recruiting patients. This was a single-blind study in which the participants were blinded. The patients who received synbiotics were assigned to the Synbiotics group, and the patients who received no synbiotics were assigned to the No-Synbiotics group. Patients were excluded if they were receiving other probiotics or were expected to be discharged or transferred out of the ICU within 3 days after admission.

Sample size calculations assumed a 30% incidence of infectious complications in the control arm based on existing published data from this ICU, a 10% incidence by the intervention, and a dropout rate of 10%. We calculated that approximately 136 patients should be enrolled to achieve a statistical power of 80% with a two-sided significance level of at least 0.05. We thus registered 150 patients as a target.

Interventions {#Sec4}
-------------

The probiotics used were Yakult BL Seichoyaku (Yakult Honsha, Tokyo, Japan), which contained 1 × 10^8^ living bacteria of the *B. breve* strain Yakult/g and 1 × 10^8^ living bacteria of the *L. casei* strain Shirota/g. The prebiotics used were galactooligosaccharides (Oligomate S-HP, Yakult Honsha). Yakult BL Seichoyaku (3 g/day) and galactooligosaccharides (10 g/day) were administered as synbiotic therapy. The synbiotics in the Synbiotics group were initiated within 3 days after admission when enteral nutrition was started via nasal tube and were continued until oral intake was initiated. Enteral nutrition using a standard polymeric diet Glucerna®-Ex (Abbott Japan Co. Ltd., Tokyo, Japan; 1 kcal/mL; 51:17:32 ratio of carbohydrate, protein, and fat; 370 mOsm/L; fiber 1.4 g/100 mL formula) was initiated as soon as possible through a nasogastric tube at 20 mL/h and advanced by 20 mL/h/day to the calorie goal. During the study period, we used 25--30 kcal/kg ideal body weight per day as the calorie goal. If infections occurred, patients were initially treated empirically for the underlying clinical syndrome and then according to the results of antibiotic susceptibility testing of the bacterial isolate causing the infection. Antibiotics were administered under the same policy during the entire study period. This study was approved by the institutional review board of Osaka University. Informed consent was obtained from the family of each patient. The clinical trial registry number is UMIN R000007633.

Determination of fecal microbiota counts {#Sec5}
----------------------------------------

Fecal samples were acquired from the subjects by swabs of the rectum. Samples were collected weekly. Samples with a cotton applicator were put into test tubes containing 1 ml RNA *later*® (Ambion, Inc., Austin, TX, USA), an RNA stabilization solution, prior to bacteriological analysis, and then the samples were incubated for 5 min at room temperature. Samples with a cotton applicator were put into test tubes prior to fecal organic acid analysis. All samples were stored at −20 °C until analysis. RNA was isolated using the method described elsewhere \[[@CR11], [@CR12]\]. Finally, the nucleic acid fraction was suspended in 1 mL nuclease-free water. The microbiota composition was analyzed using the Yakult Intestinal Flora-SCAN (YIF-SCAN®) version of a 16S and 23S rRNA-targeted reverse-transcription quantitative polymerase chain reaction (RT-qPCR) system. A standard curve was generated with RT-qPCR using the threshold cycle (C~T~) value, i.e., the cycle number when the threshold fluorescence was reached, and the corresponding cell count was determined microscopically with 4,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) staining for a dilution series of the standard strains as described elsewhere \[[@CR12]\]. To determine the types of bacteria present in the samples, three serial dilutions of an extracted RNA sample were used for RT-qPCR, and the C~T~ values in the linear range of the assay were applied to the standard curve to obtain the corresponding bacterial cell counts in each nucleic acid sample. These data were then used to determine the number of bacteria per sample. The specificity of the RT-qPCR assay using group-, genus-, or species-specific primers was determined as described previously \[[@CR11], [@CR12]\]. The quantitative analyses of *L. casei* strain Shirota \[[@CR13]\] and *B. breve* strain Yakult \[[@CR14]\] have been described previously.

Determination of fecal organic acid concentrations {#Sec6}
--------------------------------------------------

A portion of the feces was isolated, weighed, mixed with 0.15 M perchloric acid at a fourfold volume, and stored at 4 °C for 12 h. The mixture was centrifuged at 4 °C at 20,400×*g* for 10 min, and the supernatant was filtrated with a 0.45-μm membrane filter (Millipore Japan Ltd., Tokyo, Japan) and sterilized. The sample was analyzed for organic acids by high-performance liquid chromatography, which was performed with a Waters system (Waters 432 Conductivity Detector; Waters Co., Milford, MA) equipped with two columns (Shodex RS pack KC-811; Showa Denko Co. Ltd., Tokyo, Japan). The concentrations of organic acids were calculated with the use of external standards, and the reproducibility and stability of these measurements have been shown previously \[[@CR15]\].

Surveillance and definition of infection {#Sec7}
----------------------------------------

Body temperature was measured continuously. Surveillance cultures from the urine, blood, and sputum were routinely performed once a week for each patient. In cases of suspected infection, laboratory tests, chest x-rays, and computed tomography scans were performed when necessary. Bacterial infection was diagnosed based on the Centers for Disease Control definitions during the 28 days after admission \[[@CR16]\]. Enteritis was defined as the acute onset of continuous liquid stools for more than 12 h. Ventilator-associated pneumonia (VAP) refers to pneumonia that arises more than 48--72 h after endotracheal intubation \[[@CR17]\]. Bacteremia was defined as a positive blood culture after the first 3 days. Pneumonia-free days were defined as the period until patients were first diagnosed as having VAP during the 28 days after admission.

The primary outcome was enteritis, VAP, and bacteremia within 4 weeks from admission. The secondary outcomes included mortality within 4 weeks, fecal bacterial counts, and organic acid concentration.

Statistical analysis {#Sec8}
--------------------

For fecal microbiota and organic acid analysis, results are expressed as mean ± standard error (SE) values. For the statistical calculation of fecal bacterial count and organic acid concentration, a value of half of the detection limit was assigned in case the count or concentration was below the detection limit. To account for dependencies in repeatedly measured observations within a subject, a linear mixed-effect model was used with group, week, and interaction of group and week. Multiple comparisons were adjusted by Bonferroni's correction. The Acute Physiology and Chronic Health Evaluation (APACHE) II score was assessed on admission, and the initial values were used as covariates. For the incidence of infectious complications, Cox proportional hazards models were used to estimate occurrences during the first 28 days as outcomes with adjustment for APACHE II score and sex. The cumulative incidence of infectious complications was evaluated by log-rank test. A significance level of a two-sided *p* \< 0.05 was used for statistical inferences. Statistical analyses were performed using SPSS (version 22, SPSS, Chicago, IL, USA), and data are presented using GraphPad Prism, version 6.04 (GraphPad Software, La Jolla, CA, USA).

Results {#Sec9}
=======

Of the 127 patients assessed, 50 patients were excluded because other probiotics were used or the patients were too severely ill to survive. Thus, 77 patients were randomized, of whom 72 patients completed this trial, with 35 patients receiving synbiotics and 37 patients not receiving synbiotics (Fig. [1](#Fig1){ref-type="fig"}). Reasons for ineligibility included other probiotics (*B. bifidum*, *Clostridium butyricum*) being used after randomization. No adverse events occurred in any of the patients. Patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. The two groups did not differ significantly in terms of age, sex, APACHE II score on admission, comorbidities, or the cause of sepsis. The principal diseases in sepsis were respiratory, intra-abdominal, and skin/soft tissue infection. The median levels of blood lactate on admission were 33 mg/dL in the Synbiotics group and 22 mg/dl in the No-Synbiotics group (*p* \> 0.05). In the Synbiotics group, synbiotics were used for a median of 20 (interquartile range (IQR) 10--36) days.Fig. 1Study participants and flow chartTable 1Patient characteristicsNo-SynbioticsSynbiotics*p* valuePatients (*n* = 72)3735Age (years), median (IQR)74 (64--81)74 (64--82)0.73Gender (male), *n* (%)22 (59)25 (71)0.29APACHE II score, median (IQR)20 (14--26)19 (14--24)0.47Comorbidities, *n* (%) Heart disease15 (41)14 (40)0.96 Diabetes mellitus14 (38)15 (43)0.66 Immunocompromised disease8 (22)11 (31)0.34 Malignancy5 (14)7 (20)0.46 Chronic renal disease4 (11)5 (14)0.66 Pulmonary disease3 (8)3 (9)0.94Origin of sepsis, *n* (%) Respiratory16 (43)19 (54) Intra-abdominal4 (11)5 (14) Skin/soft tissue4 (11)5 (14) Urinary tract infection6 (16)1 (3) CNS0 (0)2 (6) Others7 (19)3 (9)Blood lactate, median (IQR)22 (14--60)33 (20--51)0.49*APACHE* Acute Physiology and Chronic Health Evaluation, *CNS* central nervous system, *IQR* interquartile range

In the analysis of fecal microbiota, the number of total bacteria in the Synbiotics group increased significantly compared with that in the No-Synbiotics group by a linear mixed-effect model (*p* \< 0.05). The numbers of *Bifidobaterium* and *Lactobacillus* and *Atopobium* clusters in the Synbiotics group were especially significantly higher than those in the No-Synbiotics group (Table [2](#Tab2){ref-type="table"}). In the analysis of fecal organic acids, the total organic acid concentration, especially the amounts of acetate, was significantly greater in the Synbiotics group than in the No-Synbiotics group at the first week by Bonferroni's multiple comparison (*p* \< 0.05; Table [3](#Tab3){ref-type="table"}). The statistical significance did not change after adjustment for APACHE II score on admission and the initial values as covariates.Table 2Serial changes in fecal microbiota in the Synbiotics and No-Synbiotics groupsInitial1 week2 weeks*p* valueNo-SynbioticsSynbioticsNo-SynbioticsSynbioticsNo-SynbioticsSynbioticsGroupWeekGroup×weekTotal bacteria8.1 ± 0.46.8 ± 0.47.7 ± 0.48.9 ± 0.48.3 ± 0.48.6 ± 0.40.190\< 0.05\< 0.05*Clostridium coccoides* group5.1 ± 1.04.4 ± 1.03.0 ± 1.05.5 ± 1.05.6 ± 1.16.0 ± 1.10.9460.1820.301*Clostridium leptum* subgroup6.7 ± 1.04.9 ± 1.05.5 ± 1.06.3 ± 1.05.8 ± 1.06.0 ± 1.10.2820.7270.136*Bacteroides fragilis* group5.6 ± 1.14.5 ± 1.14.8 ± 1.14.4 ± 1.17.3 ± 1.25.9 ± 1.20.4250.0860.992*Bifidobacterium*5.6 ± 1.04.1 ± 1.03.1 ± 1.06.2 ± 1.03 ± 1.16.8 ± 1.10.3580.933\< 0.05*Atopobium* cluster6.4 ± 0.94.7 ± 0.95.2 ± 0.95.9 ± 0.94.8 ± 1.05.8 ± 1.00.1330.897\< 0.05*Prevotella*1.9 ± 0.84.1 ± 0.90.9 ± 0.92.3 ± 0.91.3 ± 0.91.7 ± 0.90.0920.0610.299*Clostridium perfringens*1.9 ± 0.41.9 ± 0.52.1 ± 0.41.5 ± 0.51.7 ± 0.51.5 ± 0.50.7900.2720.660Total *Lactobacillus*4.5 ± 0.63.7 ± 0.64.1 ± 0.66.2 ± 0.63.9 ± 0.76.3 ± 0.7^a^0.6890.069\< 0.05 *L. gasseri* subgroup3.5 ± 0.53.0 ± 0.62.5 ± 0.64 ± 0.62.3 ± 0.63.9 ± 0.60.7810.7910.060 *L. brevis*1.4 ± 0.21.1 ± 0.31.3 ± 0.31.1 ± 0.31.3 ± 0.31.1 ± 0.3------ *L. casei* subgroup2.9 ± 0.52.7 ± 0.52.7 ± 0.55.6 ± 0.5^a^2.7 ± 0.55.5 ± 0.6^a^0.631\< 0.05\< 0.05 *L. fermentum*3.7 ± 0.62.5 ± 0.63.3 ± 0.63.1 ± 0.63.1 ± 0.63.6 ± 0.60.0810.5050.071 *L. plantarum* subgroup1.4 ± 0.21.2 ± 0.21.5 ± 0.21.4 ± 0.21.3 ± 0.21.2 ± 0.2------ *L. reuteri* subgroup3.2 ± 0.61.9 ± 0.62.9 ± 0.63.0 ± 0.63.0 ± 0.73.2 ± 0.70.1690.3150.170 *L. ruminis* subgroup2.7 ± 0.72.4 ± 0.72.9 ± 0.72.9 ± 0.72.6 ± 0.73.0 ± 0.70.7420.5970.441 *L. sakei* subgroup1.2 ± 0.21.5 ± 0.31.4 ± 0.32.4 ± 0.31.2 ± 0.31.4 ± 0.30.1000.8880.818*Enterobacteriaceae*5.1 ± 0.74.8 ± 0.74.9 ± 0.74.5 ± 0.75.7 ± 0.85.3 ± 0.80.7510.4110.922*Enterococcus*4.4 ± 0.63.9 ± 0.75.3 ± 0.77.3 ± 0.76.5 ± 0.76.1 ± 0.70.751\< 0.050.886*Staphylococcus*3.4 ± 0.63.0 ± 0.64.2 ± 0.64.7 ± 0.63.3 ± 0.63.7 ± 0.70.8320.5460.466*Pseudomonas*1.5 ± 0.51.5 ± 0.62.3 ± 0.62.5 ± 0.63.9 ± 0.62.2 ± 0.60.464\< 0.050.089*Lactobacillus casei* strain Shirota3.1 ± 0.33.4 ± 0.52.9 ± 0.34.3 ± 0.52.5 ± 0.34.8 ± 0.6^a^0.5310.359\< 0.05*Bifidobacterium breve* strain Yakult3.3 ± 0.32.9 ± 0.62.5 ± 0.34.9 ± 0.6†2.5 ± 0.34.8 ± 0.6^a^0.8940.253\< 0.05Values are mean ± SE (log~10~ cells/g of feces)*p* value by linear mixed-effects model^a^Statistical significance between groups determined with Bonferroni's correctionTable 3Serial changes in fecal organic acids in the Synbiotics and No-Synbiotics groupsInitial1 week2 weeks*p* valueNo-SynbioticsSynbioticsNo-SynbioticsSynbioticsNo-SynbioticsSynbioticsGroupWeekGroup×weekTotal organic acids44.2 ± 11.549.1 ± 12.146.2 ± 12116.6 ± 12.1^a^54.8 ± 12.671.4 ± 12.60.1690.1610.664Succinic acid0.1 ± 12.40.8 ± 12.43.4 ± 131.4 ± 12.449.1 ± 13.71.1 ± 13.70.3350.0780.091Lactic acid2.6 ± 5.04.4 ± 5.21.3 ± 5.116.9 ± 5.27.4 ± 5.313.1 ± 5.40.2870.0890.565Formic acid5.5 ± 4.413.4 ± 4.66.5 ± 4.510.4 ± 4.64.4 ± 4.76.9 ± 4.70.3700.3910.465Acetic acid33.9 ± 7.622.5 ± 8.025.8 ± 7.961.0 ± 8.0^a^23.5 ± 8.241.6 ± 8.30.9010.5060.058Propionic acid1.3 ± 2.62.5 ± 2.75.8 ± 2.79.1 ± 2.74.7 ± 2.93.2 ± 2.90.4910.4140.625Butyric acid0.3 ± 3.44.8 ± 3.61.8 ± 3.517.1 ± 3.60.2 ± 3.63.9 ± 3.60.6420.7310.722Values are mean ± SE (μmol/g feces)*p* value by linear mixed effects model^a^Statistical significance between groups determined with Bonferroni's correction

In the analysis of complications, the incidence of infectious complications during the 28 days after admission was significantly lower in the Synbiotics group versus the No-Synbiotics group (28.6% vs. 67.6%; *p* \< 0.05; Table [4](#Tab4){ref-type="table"}).The incidence of enteritis during the 28 days after admission was significantly lower in the Synbiotics group versus the No-Synbiotics group (6.3% vs. 27.0%; *p* \< 0.05). The incidence of VAP during the 28 days after admission was also significantly lower in the Synbiotics group versus the No-Synbiotics group (14.3% vs. 48.6%; *p* \< 0.05). The number of ventilator-free days at day 28 did not differ significantly between the No-Synbiotics group (median 7, IQR 4.5--19.5 days) and the Synbiotics group (median 14, IQR 0--21 days). There were no significant differences in the incidence of bacteremia (14.3% vs. 13.5%) or mortality (8.6% vs. 10.8%) due to multiple organ dysfunction syndrome between the two groups during the 28 days after admission (Synbiotics group vs. No-Synbiotics group). All antibiotics were administered intravenously. There were no significant differences in the duration of antibiotic administration (mean 13, IQR 8--24 days vs. 18 (10--28) days) or in the kinds of antibiotics used (4 (3--6) vs. 4 (2--6)) between the Synbiotics group and the No-Synbiotics group. Carbapenem antibiotics were used in 74.3% of the patients in the Synbiotics group and in 75.7% of patients in the No-Synbiotics group.Table 4Complications and antibioticsNo-Synbiotics (*n* = 37)Synbiotics (*n* = 35)*p* valueInfectious complications, *n* (%)25 (67.6)10 (28.6)\< 0.05 Enteritis, *n* (%)10 (27.0)2 (6.3)\< 0.05  Onset day, median (IQR)15 (9--23)9.5 (6--13)0.41 Ventilator-associated pneumonia, *n* (%)18 (48.6)5 (14.3)\< 0.05  Onset day, median (IQR)8 (5--21)8 (5--13)0.68 Bacteremia, *n* (%)5 (13.5)5 (14.3)0.92Mortality, *n* (%)4 (10.8)3 (8.6)0.84ICU stay, median (IQR)28 (17--45)23 (13--43)0.85Antibiotics, *n* (%) Carbapenem28 (75.7)26 (74.3)0.90 Ampicillin/sulbactam 18 (48.6)17 (48.6)0.99 Cephalosporin13 (35.1)12 (34.3)0.95 Vancomycin11 (29.7)11 (31.4)0.87 Quinolone8 (21.6)12 (34.3)0.22 Penicillin class5 (13.5)6 (17.1)0.66Antibiotics duration (days), median (IQR)18 (10--28)13 (8--24)0.29*ABPC/SBT* ampicillin sulbactam, *IQR* interquartile range,

In a Cox proportional hazards model, the hazard ratios for the occurrence of enteritis during the first 28 days in the Synbiotics group compared with the No-Synbiotics group were 0.18 (95% confidence interval (CI) 0.026 to 0.760; *p* = 0.036) and 0.15 (95% CI 0.021 to 0.685; *p* = 0.012), respectively, when adjusted for sex and APACHE II score. The hazard ratios for the occurrence of VAP during the first 28 days in the Synbiotics group versus the No-Synbiotics group were 0.19 (95% CI 0.057 to 0.584; *p* = 0.005) and 0.20 (95% CI 0.057 to 616; *p* = 0.004), respectively, when adjusted for sex and APACHE II score. The cumulative incidences of enteritis and VAP were significantly lower in the Synbiotics group than those in the No-Synbiotics group by log-rank test (*p* \< 0.05; Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 2The cumulative incidences of enteritis were significantly lower in the Synbiotics group than in the No-Synbiotics group by log-rank test (*p* \< 0.05)Fig. 3The cumulative incidences of ventilator-associated pneumonia (VAP) were significantly lower in the Synbiotics group than in the No-Synbiotics group by log-rank test (*p* \< 0.05)

Discussion {#Sec10}
==========

This study was a randomized controlled study to determine whether prophylactic synbiotics maintained gut microbiota and prevented the occurrence of enteritis and VAP in patients with sepsis. Sepsis treatment including massive infusion, inotropic therapy, antibiotics, and other therapies, can affect the human gut microbiota following sepsis. Shimizu et al. reported that the number of obligate anaerobes, especially *Bifidobacterium* and *Bacteroides*, were decreased and continued in patients with systemic inflammatory response syndrome (SIRS) \[[@CR18], [@CR19]\]. The number of obligate anaerobes were around 10 (log~10~ colony-forming units (CFUs)/g of feces) on average in normal people and postoperative patients \[[@CR20], [@CR21]\]. In the present study, the number of total bacteria tended to decrease to about 6 (log~10~ CFUs/g of feces) on average in the No-Synbiotics group, which was much less than that in normal people and postoperative patients. The numbers of pathogenic bacteria such as *Enterococcus* and *Pseudomonas* increased significantly within 1 week in both groups (*p* \< 0.05), but they did not reach statistical significance with the interaction of group and week. The numbers of pathogenic bacteria, such as total facultative anaerobes, and also those of total obligate anaerobes were the significant prognostic factors in patients with SIRS \[[@CR4]\]. These findings suggest that sepsis influenced the microbiota of the patients and might be related to the occurrence of subsequent complications.

Synbiotics, as a combination of probiotics and prebiotics, have been reported to promote immunity against severe injuries such as trauma and infection. Although the mechanisms of probiotics have not yet been clarified, one of the important factors is microorganism-host crosstalk such as microorganism-associated molecular patterns (MAMPs) of probiotics and pattern recognition receptors (PRRs) of the gastrointestinal mucosa \[[@CR22]\]. The most well-known PRRs are Toll-like receptors (TLRs). MAMPs consist of flagellin, lipopolysaccharide, peptidoglycan, and other factors. For example, flagellins of the probiotic *Escherichia. coli* Nissle 1917 were shown to induce beta-defensin via TLR5 \[[@CR23]\]. Asahara et al. reported that intraluminal acetate produced by *B. breve* strain Yakult could inhibit the toxin in a mouse model of toxin-producing *E. coli* infection \[[@CR24]\]. The *L. casei* strain Shirota was effective against multidrug resistant *Salmonella enterica* serovar Typhimurium DT104 infection in a 5-FU treated mouse model \[[@CR25]\]. In the present report, administered *B. breve* strain Yakult and *L. casei* strain Shirota might inhibit pathogenic bacteria and toxins through signal interaction and prevent septic complications. Also, the number of total bacteria was significantly higher in the Synbiotics group. The numbers of *Bifidobacterium* and total *Lactobacillus* in the Synbiotics group were especially increased over those in the No-Synbiotics group. Looking at total *Lactobacillus*, the *L. gasseri* subgroup and *L. fermentum* tended to increase more in the Synbiotics group than in the No-Synbiotics group. *L. gasseri* has a role in vaginal homeostasis and *Helicobacter pylori* infection and improvement of diarrhea \[[@CR26]\]. *L. fermentum* is reported to enhance the immunologic response of influenza vaccination \[[@CR27]\]. These findings suggest that synbiotics not only increase the number of administered bacteria but also increase their genus groups and other microbiota, which could lead to the maintenance of gut microbiota. In previous studies, synbiotics could maintain gut microbiota following SIRS \[[@CR8]\] and major surgeries \[[@CR21]\]. Synbiotics could have a supplemental effect to increase the number of microbiota.

Short-chain fatty acids (SCFAs) consist of acetic, propionic, and butyric acids with 2--4 carbon atoms. Anaerobic metabolism of peptides and proteins by the microbiota produces SCFAs that all have important functions in host physiology. SCFAs are utilized mainly by intestinal epithelial cells as energy substrates, and some are absorbed into the portal flow to the liver and utilized as systemic energy sources \[[@CR28]\]. SCFAs bind to the G-protein-coupled-receptor 43 (GPR43). Maslowski et al. reported that GPR43-deficient mice showed exacerbation of inflammation in models of colitis, arthritis, and asthma \[[@CR29]\]. Asahara et al. reported that intraluminal acetate produced by synbiotics could inhibit the toxin in a mouse model of toxin-producing *E. coli* infection \[[@CR24]\]. In the present report, the synbiotic-treated group had significantly maintained gut microbiota and organic acids, especially acetate. Increased levels of acetate might attenuate inflammation to reduce septic complications. Butyric acid in the feces of the patients decreased in both groups from the normal values (16.6 ± 6.7 μmol/g (mean ± SD)) described in our previous paper \[[@CR18]\], which could be due to the decreased numbers of bacteria and lactate levels. The differences in the values did not reach statistical significance between the groups in the present study.

Regarding diarrhea in the ICU, Bleichner et al. reported that in 128 ICU patients the number of days with diarrhea was reduced in patients treated with *Saccharomyces boulardii* \[[@CR30]\]. In our previous study of SIRS, the patients treated with synbiotics had a significantly reduced incidence of diarrhea compared with the controls \[[@CR8]\]. In the present research, synbiotics showed beneficial effects against complications of enteritis in the patients with sepsis. Prophylactic synbiotics could maintain gut microbiota and reduce the incidence of enteritis. Further study is needed to determine the mechanisms of the prevention of diarrhea.

There are several reports on the effectiveness of probiotics and synbiotics on the incidence of VAP \[[@CR31]\]. Morrow et al. \[[@CR32]\] reported that the incidence of VAP in patients treated with *L. rhamnosus* GG was significantly lower than that in the controls (19.1% vs. 40.0%) in 138 ICU patients. Also, probiotic administration significantly reduced oropharyngeal and gastric colonization of pathogenic species. Fukuda et al. reported that *Bifidobacteria* continue to generate acetate through ATP-binding cassette-type carbohydrate transporter and prevent translocation in a mouse model \[[@CR33]\]. Also, intraluminal acetate could increase the level of tight junction proteins including claudin-1, occludin, and ZO-1, which could prevent bacterial translocation in a mouse model of *Acinetobacter baumannii* infection \[[@CR34]\]. In our report, the synbiotic-treated group had significantly maintained gut microbiota and organic acids, especially acetate. Increased levels of acetate and lactate might inhibit intraluminal toxins and maintain tight junctions. These changes indicated that synbiotic treatment could have beneficial effects on microbiota and reduce the development of VAP. However, other clinical reports showed no significant difference in the occurrence of VAP in the ICU \[[@CR35]\]. One of the reasons is the difference in administered bacteria. In a mouse model, the antitoxic effects and organic acid concentration of probiotics such as *Bifidobacterium* and *Lactobacillus* are different with species \[[@CR24], [@CR25], [@CR33]\]. In a rabbit infective endocarditis model, the incidence of infection was different with *Lactobacillus* species \[[@CR36]\]. Besselink et al. \[[@CR37]\] reported that mortality rates with six kinds of bacteria were significantly higher than those without these bacteria in the PROPATRIA study (16% vs. 6%). However, the incidence of infectious complications showed no significant differences and, in addition, the study has been criticized from multiple perspectives \[[@CR38]\]. The effects of synbiotics for gut microbiota might be different with different species or combinations of bacteria and different diseases. Further analysis is needed to determine the appropriate probiotic species for preventing VAP and to elucidate the underlying mechanism of synbiotic treatment.

This study has some limitations. There is a source of potential bias in that gut microbiomes are different with different backgrounds such as geography, ethnicity, and lifestyle \[[@CR39]\]. Thus, innate immunity via gut microbiota could be different against pathogenic bacteria. The modulation of gut microbiota by synbiotics might be different with these backgrounds. Second, there is limited generalizability. Because patients were collected through a tertiary center after being transferred directly from the emergency medical system in a limited area, the studied patients do not represent the national population, and the ethnicity of the subjects was only Asian. Therefore, caution is required in applying the findings to a larger worldwide population. Third, this is a quantitative research study of the main subset of microbiota, and changes in other whole bacteria were not evaluated. The bacteria influenced by synbiotics in the gut microbiome could be a target for further study. Fourth, the number of patients was lower than expected because of the small number of sepsis patients requiring mechanical ventilation with early enteral nutrition. Additional multicenter studies are needed to solve this problem. Fifth, cost-effectiveness analysis using measures such as the number needed to treat could be needed for further research to apply synbiotics clinically.

Conclusions {#Sec11}
===========

The administration of synbiotics increased the levels of beneficial bacteria and SCFAs. The beneficial alterations of gut microbiota and environment may decrease the incidence of enteritis and VAP in patients with sepsis. Further research is needed to investigate the effects of synbiotic treatment.

APACHE

:   Acute Physiology and Chronic Health Evaluation

CFU

:   Colony-forming unit

CI

:   Confidence interval

C~T~

:   Threshold cycle

GPR43

:   G-protein-coupled-receptor 43

ICU

:   Intensive care unit

IQR

:   Interquartile range

MAMP

:   Microorganism-associated molecular pattern

PRR

:   Pattern recognition receptor

RT-qPCR

:   Reverse-transcription quantitative polymerase chain reaction

SCFA

:   Short-chain fatty acid

SIRS

:   Systemic inflammatory response syndrome

TLR

:   Toll-like receptor

VAP

:   Ventilator-associated pneumonia
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